| Beam Therapeutics is a biotechnology company. Within its ex vivo platform, Co. has identified three development candidates. BEAM-101 reproduces single base changes seen in individuals with Hereditary Persistence of Fetal Hemoglobin to potentially protect them from the effects of mutations causing sickle cell disease or beta thalassemia. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. We show 8 historical shares outstanding datapoints in our BEAM shares outstanding history coverage, used to compute BEAM market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BEAM market cap history over the course of time is important for investors
interested in comparing BEAM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BEAM versus a peer is one thing; comparing
BEAM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BEAM can fluctuate over the course of history.
With this page we aim to empower investors researching BEAM by allowing them to research the BEAM market cap history.